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Summary Estimation of FGF-3 oncogene amplification in DNA samples extracted from paraffin embedded
sections of 136 ovarian cancer samples was carried out by a quantitative PCR method. The aim of this study
was to elucidate a possible association of FGF-3 copy numbers with established prognostic factors such as
age, histology, FIGO stage, grading, postoperative residual tumour mass, ascites, hormone receptor content
and preoperative CA 125 serum levels. In addition, correlation of FGF-3 amplification with overall survival of
the patients was assessed. There was a borderline positive correlation between preoperative CA 125 serum
levels and the degree of amplification of the FGF-3 gene (P = 0.06). A statistically significant association of
FIGO-stage with FGF-3 copy number could be found (P = 0.008). No correlation between FGF-3
amplification and overall survival was noted. The data combine to suggest that FGF-3 is an indicator of
aggressiveness of ovarian cancer.
The FGF-3 (Fibroblast growth factor 3) gene was found to
be located at the second known common integration site for
Mouse Mammary Tumor Virus (MMTV) (Peters et al., 1983;
Dickson et al., 1984; Peters et al., 1984). The MMTV does
not possess a viral oncogene and transforms cells by activa-
tion of a cellular protooncogene in the vicinity of the proviral
integration site. The FGF-3 gene was thought to be a can-
didate gene for proviral activation in malignant transforma-
tion of the breast. The gene was initially termed INT-2.
Both the genomic sequence of the FGF-3 gene as well as
the amino acid sequence of the predicted protein revealed a
high homology to the sequences of the acidic and basic
fibroblast growth factors (Dickson & Peters, 1987). The
human homologue of FGF-3 has been mapped to chrom-
osome 1 lql3 (Casey et al., 1986; Moore et al., 1986).
Although the relevance of FGF-3 to human carcinogenesis
had not been demonstrated various observations in mam-
mary tumours had suggested that FGF-3 is a proliferation
marker (Adnane et al., 1989; Liderau et al., 1988). It was
described that amplification of FGF-3 correlated with steroid
receptor levels, recurrence and lymph node status in mam-
mary carcinoma (Liderau et al., 1988; Adnane et al., 1989).
In addition, two other genes, PRADI and EMS1 (Schuuring
et al., 1992), have been described recently which are also
located on chromosome llql3. They were found to be co-
amplified with FGF-3, HSTF1 and BCL1 in 40 breast and
squamous cell carcinomas as well as nine cell lines. PRADI
and EMS1 overexpression was found to correlate with
amplification (Schuuring et al., 1992). FGF-3 overexpression
however was not observed in tumours which exhibit llql3
amplification. The two newly discovered genes PRADI and
EMS1 that possibly belong to an amplification unit of about
2,000 kb could contribute to the growth advantage of
tumours with llql3 amplification. The FGF-3 gene which is
located within this region could serve as marker for llql3
amplification. The present experiments were performed to
investigate whether FGF-3 amplification could be an
indicator for poor prognosis.
Patients and methods
One hundred and thirty-six patients operated on for primary
ovarian cancer at three different gynecologic departments
(Department of Gynecology and Obstetrics/Hanusch Medical
Center, 1st Department of Gynecology and Obstetrics/
University of Vienna, Department of Gynecology and
Obstetrics/Lainz Medical Center) between 1983 and 1989
were studied. Patients with borderline tumours were excluded
from survival statistics, because of their different biologic
behaviour.
We compared the amplification of FGF-3 with classical
prognostic factors such as FIGO stage, histologic grading,
residual tumour, ascites, hormone receptors (estrogen, pro-
gesterone) and CA 125 levels prior to and after surgery. The
tumour status was evaluated by CT or sonography according
to UICC criteria. The tumour stages were assessed by FIGO
criteria as of 1985. The histologic grading was according to
the criteria established by Day et al. (1975), i.e. highly
differentiated tumours were classified as grade 1 and
undifferentiated tumours were classified as grade 3. Car-
cinomas with low malignant potency were classified as grade
0 and were defined as borderline tumours (Day et al., 1975).
Histologic tumour type was evaluated according to WHO
criteria (Serov et al., 1973).
All patients underwent abdominal hysterectomy with
bilateral removal of adnexae and omentectomy. Pelvic lym-
phonodectomy was only performed with a residual tumour
mass <2 cm. Postoperatively, all patients received a poly-
chemotherapeutic regimen containing cisplatin (six cycles,
dosage 75-100mgm2 cisplatin). A standardised follow-up
was performed in an oncologic OPD in 3-monthly intervals
during the first 2 years, followed by 6-monthly intervals
thereafter.
Tissue samples were frozen in liquid nitrogen immediately
after surgery. Preparation of cytosol and nuclei was carried
out by homogenising the tissue samples by an Ultra Turrax
in 50 mM phosphate buffer at a pH of 7.5. All procedures
were carried out at 4°C. The homogenate was centrifuged at
50,000 g for 1 h. The supernatant containing the cytosol
fraction was used to determine the estrogen receptor (ER)
and the progesterone receptor (PgR) concentration. ER and
PgR levels were determined by a dextran coated charcoal
method by simultaneous incubation with '25I-estradiol and
3H-R5020 as ligands as decribed previously (Grill et al.,
1984). Data were processed by Scatchard plot analysis (Scat-
chard, 1949). Cut-off points for ER and PgR were set at
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10 fmol mg-' cytosol protein. Tumours with ER and PgR
content <10 fmol mg-' were classified as hormone receptor
negative.
Serum levels of CA 125 were determined by radio-
immunoassay with materials obtained from CIS, GIF-sur-
Yvette, France. Intra- and interassay coefficients ofvariations
were between 5% and 9%. Blood was sampled 1 day before
surgery for preoperative CA 125 serum levels and 4 weeks
after surgery for postoperative ones, respectively.
High molecular weight DNA was extracted from frozen
tissue sections of about 500 mg of ovarian cancer tissue by
standard methods (Sambrook et al., 1989). The OD260 was
measured in order to estimate the DNA content of the
solution. Dot blotting was carried out by fixing 5 1tg of DNA
to nylon membranes according to standard protocols (Sam-
brook et al., 1989). The P-actin gene was used as reference
gene in dot blot experiments. DNA from frozen placenta
tissue served as single copy control.
PCR (polymerase chain reaction) experiments were per-
formed with DNA extracted from paraffin embedded sections
of ovarian cancer tissue. Two 10 tm sections were de-
paraffinised with 1.5 ml isooctane at 70°C for 5 min. After
four extraction cycles the samples were dried in a SpeedVac
concentrator and incubated with 75Ild lysis buffer (1 mM
CaC12, 0.5% Tween 20, 10 mM Tris HCI, pH 8.0) containing
20 tig proteinase K at 56°C for 4 h. After boiling the samples
for 20 min the supernatant was used for PCR runs. Primers
PCO3 (5'ACACAACTGTGTTCACTAGC3') and KM38
(5'TGGTCTCCTTAAACCTGTCTT3') were used for the P-
globin gene as published previously (Saiki et al., 1987). These
oligonucleotides yielded a 168 bp PCR product. Primers
FGF3a (5'CAGAAGCAGAGCCCGGATAA3') and FGF3b
(5'ACGCCAAGATGTCGCCAGGA3') were designed by a
computer programme (Rychlik & Rhoads, 1989). These
FGF-3 primers resulted in a 130 bp PCR product. All
primers were obtained from Biomedica, Vienna, Austria.
Threelal of the DNA extraction supernatant were vortexed
with 97 itl of reaction mix (0.2 mM dNTP, 0.5 AM of each
primer: FGF3a, FGF3b, PCO3, KM38, 3 units/1001gl
Promega-Taq polymerase, 50 mM KCI, 5 mM MgCl2, 10 mM
Tris.HCI pH 8.4, 0.001% gelatine, 0.1% Triton X 100). The
PCR samples were incubated in a Thermocycler (Bio-med
PCR Processor; start cycle: 94°C; 55°C; 72°C for 2 min each;
30 cycles: 94°C for 30 s; 55°C for 30 s; 72°C for 1 min 30 s;
extension time 1 s each cycle and 5 min last step). The PCR
products were separated by agarose gel electrophoresis,
visualised by ethidium bromide staining and scanned by a
densitometer. The oncogene copy number was estimated
from the ratio of peak areas using placental DNA as single
copy control. The P-globin gene which maps to the same
chromosome as the FGF-3 gene was used as a reference in
order to account for DNA ploidy in the tumour samples.
Statistics
For basic data description common statistical parameters
such as frequency, mean values and percentages are given.
Correlations were quantified by Kendall's tau-c and were
tested according to Brown and Benedetti (Brown & Bene-
detti, 1977). Contingencies in tables of nominal variables
were tested by the chi-square test and by Kruskal-Wallis
non-parametric analysis. The level of significance was chosen
at P<0.05.
The probability of overall survival was assessed according
to Kaplan and Meier and was calculated by the Mantel-Cox
log-rank test (Kaplan & Meier, 1958; Mantel, 1966).
Results
The results of the PCR method correlated with dot blot
assays showing a correlation coefficient of 0.80, a slope of
0.74 and an intercept of 0.31 in linear regression analysis
(data not shown). These experiments were performed to
demonstrate the validity and reproducibility of the newly
developed PCR procedure. In 136 patients with epithelial
ovarian cancer the FGF-3 copy numbers were determined by
this quantitative PCR. The median age of the patients was 61
years with a range between 27 and 88 years. The women were
observed over a period of 12 to 79 months with a median
follow-up period of 28 months. All other patient characters
such as FIGO-stage, histologic grading, histologic type,
status of hormone receptors, ascites and residual tumour
mass are shown in Table I.
Tumour samples with less than 1.5 copies were defined as
not amplified and classified as single copy tumours, whereas
tumour samples with more than 1.5 copies were defined as
amplified (Figure 1). One hundred and nine out of 136 (80%)
tumour samples showed single copy FGF-3 oncogene,
whereas 27/136 (20%) ovarian tumours had an amplified
FGF-3 gene with copy numbers between 1.5 and 3.5. Tables
I and II show these data with regard to amplification of the
FGF-3 oncogene.
Preoperative CA 125 levels were above the established
cut-off of 35 IU ml-' in 112/136 (82.6%) patients and a
borderline significance (P = 0.06) for patients with amplified
FGF-3 gene as compared to patients with single copy gene
was noted (Table II). In 74/136 (54.8%) subjects hormone
FGF-3
3-globin
1 2 3 4 5 6 7 8 M
Figure 1 FGF-3 PCR products on an agarose gel. Lane 1:
Placenta; lanes 2, 6, 7: samples with single copy FGF-3 gene;
lanes 3, 4, 5, 8: samples with amplified FGF-3 gene; lane M:
molecular weight marker (pBR322/Haelll digested).
Table I Clinicopathological parameters and association with FGF-3
copy numbers
FGF-3 single copy FGF-3 amplified CHI-square
FIGO-stage
I 30 27.52% 0
II 4 3.67% 3 11.11%
III 65 59.63% 19 70.37% P= 0.008
IV 10 9.17% 5 18.52%
Histol. grade
GO 8 7.41% 0
GI 21 19.44% 3 11.11% P = 0.17
GII + GIII 79 73.15% 24 88.89% n.s.
Histology
serous 65 59.63% 17 62.96%
mucinous 14 12.84% 1 3.70%
endometr. 5 4.59% 2 7.41% P= 0.671
undiff. 13 11.93% 3 11.11% n.s.
clearcell 6 5.50% 1 3.70%
other 6 5.50% 3 11.11%
Ascites
yes 54 50.00% 12 44.44% P = 0.60
no 54 50.00% 15 55.56% n.s.
Residual tumour mass
none 44 40.37% 6 22.22%
<2cm 23 21.10% 9 33.33% P = 0.173
>2 cm 42 38.53% 12 44.44% n.s.
Steroid receptor levels
pos. 40 36.70% 11 42.30%
neg. 18 16.50% 5 19.20% P= 0.74
none 51 46.80% 10 38.50% n.s.1124 A. ROSEN et al.
Table II Association ofsteroid receptor levels and preoperative CA 125 serum levels
with FGF-3 copy numbers
FGF-3 FGF-3 Kruskal-Wallis
single copy amplified CHI-square
Age median 60.1 a 57.8 a P=0.17
(n = 136) range (27-88) (39-80) n.s.
Pg-receptor median 0 fmol ml- 8 fmol ml-' P = 0.28
(n = 74) range (0-467) (0-221) n.s.
E-receptor median 12.5 fmol ml-' 11 fmol ml-' P = 0.81
(n = 75) range (0-196) (0-166) n.s.
CA 125 median 193 IEml-' 382IEml-' P=0.06
(n = 134) range (3.5-> 10.000) (8-> 10.000)
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Figure 2 Survival probability in epithelial ovarian cancer by
Kaplan-Meier analysis. Single copy FGF-3 oncogene vs amplified
FGF-3 oncogene.
receptor levels could be estimated (Table II). In the single
copy group there were 40 women (36.7%) with positive
hormone receptor findings vs 11 (42.3%) women in the
amplified group. Eighteen (16.5%) patients with negative
hormone receptor findings in the single copy group were
found compared to 5 (19.2%) patients with negative findings
in the amplified group. No significant difference was
detected.
Thirty out of 136 patients were FIGO stage I and all of
them showed single copy FGF-3 oncogene. This correlation
was highly significant (P = 0.008). Concerning the histologic
grade, the FGF-3 gene turned out to be not amplified in all
patients with GO turnouts. Fifty out of 136 patients did not
have any residual tumour. In 44 of these 50 cases a single
copy FGF-3 gene was found and 6/50 cases contained an
amplified FGF-3 gene. No significant association of age,
estrogen receptor and progesterone receptor status with
FGF-3 amplification was observed.
No significant association of overall survival with FGF-3
amplification was found (Figure 2).
Discussion
This study provides the first evidence of the amplification of
the FGF-3 oncogene in patients with ovarian cancer. In
breast cancer the FGF-3 oncogene seems to be one of the
three most frequently amplified oncogenes (Adnane et al.,
1989). Amplification frequencies have been reported to range
between 4% and 23% of cases of mammary carcinoma
(Varley et al., 1988; Zhou et al., 1989). In the present study
on ovarian cancer the FGF-3 gene was found to be amplified
in a similar percentage of cases, since 20% of the ovarian
cancer samples investigated were found to have an amplified
FGF-3 oncogene.
Prognostically favourable groups could benefit from the
presence of a single copy of the FGF-3 gene, because all
FIGO stage I, all GO and 88% of the cases with no residual
tumour had a single copy number. Except for the association
of FIGO stage with FGF-3 copy number (P = 0.008) no
other correlations between FGF-3 amplification and clinico-
pathological indices could be found. In addition, no influence
of FGF-3 copy number on overall survival was noted. This
could at least partly be explained by the small patient
numbers in this investigation.
CA 125 is a tumour antigen, which was reported by Bast
et al. in 1983, and its validity as a prognostic factor was
subsequently confirmed (Sevelda et al., 1987; Sevelda et al.,
1989; Rosen et al., 1990; Sevelda et al., 1991). Significant
correlation between CA 125 and the classical prognostic
factors such as residual tumour mass, histological grading,
ascites and FIGO stage was reported recently (Makar et al.,
1992). These parameters characterise the biologic properties
of a tumour. No correlation (P = 0.06) between preoperative
CA 125 serum levels and FGF-3 amplification could be
observed in the present investigation. The borderline associa-
tion between CA 125 and FGF-3 amplification as well as the
significant correlation between FIGO stage and oncogene
amplification combine to suggest that FGF-3 could con-
tribute to aggressiveness and tumour proliferation. Larger
numbers of patients should however be investigated to sup-
port this notion. In addition, levels of FGF-3 expression in
ovarian tumours with and without 11q13 amplification
should be studied in order to shed light on the possible role
of FGF-3 as a proliferation marker.
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